Introduction
In the last two decades, substantial progress has been made in the prevention and treatment of CINV. However, CINV remains still one of the most distressing side eff ects of chemotherapy, impairing patient's quality of life, leading to non-compliance with treatment, dose reductions, and, as a consequence, may compromise chances of treatment success.
Th e Multinational Association of Supportive Care in Cancer (MASCC) suggests the classifi cation of the chemotherapeutic agents according to their emetic potential into four emetic risk groups (minimal, low, moderate, and high). As new antineoplastic agents have been developed, these agents have been added to the emetogenic classifi cation scheme (Table 1) . With the increasing use of oral agents used in extended regimens of continuous daily use, emetogenicity of these agents has to be newly defi ned and therefore oral agents are ranked separately from intravenous agents (Table 2) , recognizing their diff erent schedules of administration. As oral agents rarely induce delayed emesis, antiemetic prophylaxis is only recommended on day 1.
However, current guidelines are only considering the emetogenic potential of the chemotherapeutic agent itself and not the patient-related risk-factors which might lead to an underestimation of the emetogenic risk and, as a consequence, to an inadequate antiemetic prophylaxis. Furthermore, this classifi cation does not take into account the emetogenic potential of combinations of targeted drugs and does not include nausea, which is not controlled as well as emesis.
Antiemetic agents
Of the various antiemetics currently available, 5-hydroxytryptamine-3(5-HT 3 ) receptor antagonists, neurokinin-1 (NK 1 ) receptor antagonists and corticosteroids are the most eff ective agents [1] . memo 1/2012 Chemotherapy-induced nausea and vomiting short review 48 © Springer-Verlag the prophylaxis of acute high and moderately emetogenic chemotherapy when given at equivalent doses [2, 3] . However, the fi rst-generation 5-HT 3 receptor antagonists are not effective in the control of delayed CINV, and there is no clinical evidence to justify their use beyond 24 h after chemotherapy for the prevention of delayed emesis [4] . Th e only 5-HT 3 receptor antagonist which has shown clinical effi cacy in controlling delayed CINV is the second-generation 5-HT 3 -RA palonosetron.
Palonosetron is characterized by its higher binding affi nity to the 5-HT 3 receptor, its signifi cantly longer half-life of approximately 40 h and its ability to trigger 5-HT 3 receptor internalization [5] . Clinical trials on chemotherapy of high and moderately emetogenic potential have shown that palonostron is at least equivalent to the fi rst-generation 5-HT 3 -RA in the control of acute CINV in moderately [6] -and in highly emetogenic chemotherapy (HEC) [7, 8] , and superior in the control of delayed CINV [9, 10] . Th e study by Aapro et al. [7] demonstrated signifi cantly higher complete response rates during the delayed (24-120 h) and overall phases (0-120 h) when Palonosetron was given with concomitant dexamethasone compared to ondansetron plus dexamethasone in HEC. However, only two-third of patients received pretreatment with dexamethasone. Furthermore, a study by Saito et al. [9] could demonstrate superiority of palonosetron when administered with dexamethasone in the control of CINV in the delayed phase compared to granisetron plus dexamethasone. Regarding the dosage, a recent meta-analysis could prove equivalent in terms of effi cacy between the 0.25-and the 0.75 mg doses [11] . Based on these studies, Palonosetron was approved for the prevention of acute CINV in HEC and MEC and, as the only 5-HT 3 -RA for the prevention of delayed nausea and vomiting in MEC. However, no study results of palonostron in combination with an NK 1 -RA are available so far.
Neurokinin-1 (NK 1 ) receptor antagonists
Aprepitant, a selective antagonist of the neurokinin 1 neurotransmitter receptor, demonstrated superior effi cacy with an additional improvement in the prevention of acute emesis of 10-15% and 20-30% in delayed CINV, when combined with a 5-HT 3 -RA and dexamethasone [12] . Additional NK 1 -RA such as casopitant, netupitant and rolapitant have either shown clinical promise or are still under investigation [13] . Fosaprepitant, a single day intravenous antiemetic agent, which is converted within 30 minutes into aprepitant, has demonstrated equivalence with aprepitant for nausea and emesis control in HEC and was recently approved to replace oral aprepitant [14] [15] [16] . Of note, a dose of 115 mg fosaprepitant is bioequivalent in its area under the curve to aprepitant 125 mg.
Tab. 1: Emetogenic classification of intravenous chemotherapeutic agents (Adapted from [18] )
Tab. 2: Emetogenic classification of oral chemotherapeutic agents (Adapted from [18] )
Corticosteroids Th e addition of corticosteroids to a 5-HT 3 -RA containing antiemetic regimen or an NK 1 -RA has markedly enhanced the control rates of both, acute and delayed CINV. Dexamethasone is the preferred steroid in the prophylaxis of acute and delayed CINV of either moderate or high emetogenic potential. [3, 18] . Th e marginal changes and the management of chemotherapy-induced emesis in diff erent situations (Fig. 1) will be discussed here.
Prevention of acute and delayed CINV in highly emetogenic chemotherapy (HEC)
With the introduction of Aprepitant to a 5-HT 3 -RA and dexamethasone regimen, acute and delayed emesis following chemotherapy of high emetogenic risk, could be signifi cantly improved [19] [20] [21] most likely due to the improvement of CINV in the fi rst 24 h. Th is eff ect could be maintained over multiple cycles of chemotherapy [22, 23] , however, the control of nausea was only improved in the delayed period in only one study [20] . Based on the results of these studies, a triple therapy consisting of single doses of a 5-HT 3 -RA, dexamethasone and aprepitant/fosaprepitant given before chemotherapy is recommended. Th is triple therapy is also a recommended treatment in patients receiving an anthracycline plus cyclophosphamide (AC) combination [21] , which was recently reclassifi ed as a highly emetogenic chemotherapy regimen based on the high emetic potential of these two agents. 
Antiemetic treatment in HEC

Prevention of acute and delayed CINV in moderately emetogenic chemotherapy (MEC)
In non-AC MEC regimens, the updated ASCO and MASCC/ ESMO guidelines recommend the double therapy of a 5-HT 3 -RA and a corticosteroid as standard prophylaxis. Th e addition of aprepitant might be also benefi cial in the prevention of CINV in patients with MEC [24] with the additional advantage of abbreviating dexamethasone dosing, however, additional 
Prevention of acute and delayed CINV in low and minimal emetogenic chemotherapy
In patients with no prior history of CINV submitted to low emetogenic chemotherapy, a single agent such as dexamethasone (8 mg oral or iv), a 5-HT 3 -RA or a dopamine RA should be used as prophylaxis on day one, whereas for days 2 and 3 no prophylaxis is recommended. In chemotherapy with minimal emetogenic potential no antiemetic treatment should be administered routinely.
Multiday chemotherapy
For patients receiving multiday chemotherapy, antiemetics should be administered according to the emetogenic risk class of the antineoplastic agent, and should be given on each day of chemotherapy and for additional 2 days after. Palonostron is the only 5-HT 3 -RA approved for delayed CINV, therefore the combination of palonosetron and dexamethasone daily during each day of chemotherapy might be a promising treatment approach in this setting [25] . However, a specifi c dosing schedule still needs to be defi ned. Instead of taking a serotonin antagonist daily, patients can also be off ered the granisetron transdermal patch that delivers therapy over multiple days in high-or moderate-risk chemotherapy [26] . Th e severity of CINV in patients receiving multiday cisplatin-based chemotherapy can be improved by using a combination of a 5-HT 3 -RA plus dexamethasone for acute, and dexamethasone alone for delayed nausea and vomiting. Th e addition of an NK 1 -RA to the standard combination of a fi rstgeneration 5-HT 3 -RA and dexamethasone might have an additional benefi t [27] and the recently updated ASCO guidelines recommend the additional use of aprepitant for patients receiving 5-day cisplatin therapy [3] .
In addition, olanzapine, a thienobenzodiazepine with a high affi nity to several receptors involved in the CINV pathway such as dopamine, serotonine and histamine receptors, has demonstrated activity in the prevention of acute and delayed CINV in patients receiving MEC or HEC [28] [29] [30] . Th e combination of olanzapine with standard 5-HT 3 -RA and dexamethasone might be another reasonable treatment strategy to control CINV in multiday chemotherapy regimens.
Antiemetic salvage therapy
In patients who fail antiemetic prophylaxis and/or rescue therapy despite optimal prophylaxis, clinicians should reevaluate emetic risk, disease status, concurrent illness and medication. According to the current ASCO and NCCN guidelines, switching to a diff erent 5-HT 3 -RA or adding other agents such as lorazepam or alprazolam, dopamine antagonists such as high-dose intravenous metoclopramide or olanzapine or cannabinoids, are reasonable treatment options for patients refractory or intolerant to 5-HT 3 -RA, dexamethasone and NK 1 -RA [17] . Of note, aprepitant is only approved for the prevention of CINV and should not be used in the treatment of existing nausea and vomiting.
Anticipatory nausea/vomiting
Anticipatory nausea and vomiting occur prior to the administration of chemotherapy and is triggered by the adverse memory of prior CINV. Its incidence ranges from 10-45%, with predominance of nausea. Prevention of CINV with the most active antiemetic regimens is therefore of utmost importance. However, if anticipatory nausea and emesis occur, behavioural therapy with systematic desensitization is suggested [3] .
Conclusion
Despite a wide armamentarium of antiemetic drugs, there is still much to be achieved in the prediction and treatment of CINV. Besides the remarkable improvement in the control of vomiting, nausea remains a signifi cant problem in patients receiving moderately and highly emetogenic chemotherapy, also because the emetic risk classifi cation does not include nausea. NK 1 -RA and 5-HT 3 -RA could not demonstrate major effi cacy in the control of nausea and the identifi cation and implementation of antinausea agents into antiemetic regimens is highly warranted.
Patients receiving antiemetic treatment as recommended by international guidelines have an improved control of CINV, leading to a better treatment compliance and improvement in quality of life, however, only 50% of the patients receive antiemetic prophylaxis as recommended by the guidelines, causing a signifi cantly worse protection from CINV, particularly for delayed CINV [31] . Th erefore, the implementation of treatment guidelines in clinical practice is the pre-condition for eff ective prophylaxis of CINV.
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